ADC Therapeutics reported preliminary net product revenue for the third quarter 2026 of $21 million, compared to $16 million in the prior year period. The company highlighted significant clinical advancements for ZYNLONTA across multiple indications, including updated Phase 1b data in large B-cell lymphoma and Phase 2 data in marginal zone lymphoma. Additionally, the company executed a strategic financial restructuring, including an $86.6 million private placement and loan refinancing to extend its cash runway into 2029.
Key Highlights
- The LOTIS-7 Phase 1b trial of ZYNLONTA plus glofitamab achieved an 88.7% overall response rate and a 75.3% complete response rate among 97 efficacy-evaluable patients.
- Phase 2 investigator-initiated trial in marginal zone lymphoma demonstrated a 93% overall response rate and a 74.4% complete response rate, with a two-year progression-free survival rate of 90.8%.
- Preliminary cash and cash equivalents totaled $189.2 million as of September 30, 2026, which included $13 million in one-time severance and retention payments.
- The Phase 3 LOTIS-5 confirmatory trial met its primary endpoint with a PFS hazard ratio of 0.73, though management is evaluating regulatory pathways following FDA feedback regarding a Grade 5 safety imbalance.